Biofrontera (BFRI) grants RSUs and stock options to CCO

Rhea-AI Filing Summary

Biofrontera Inc. reported that Chief Commercial Officer George Patrick Jones acquired new equity-based compensation. He received 50,000 restricted stock units, each representing a contingent right to one share of BFRI common stock awarded for no consideration.

He also received an option for 50,000 shares with a grant price of $0.00. The option vests in two equal installments on September 4, 2026 and March 4, 2027. The restricted stock units vest in two equal yearly installments beginning March 4, 2027, and each vested unit will be settled in shares, cash, or a combination within 60 days at the company’s discretion.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Jones George Patrick

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	50,000	$0.00	--
Grant/Award	Employee stock option (right to buy)	50,000	$0.00	--

Holdings After Transaction: Restricted Stock Units — 50,000 shares (Direct); Employee stock option (right to buy) — 50,000 shares (Direct)

Footnotes (1)

1. The option vests in two equal installments, the first of which will take place on September 4, 2026 and the second of which will take place on March 4, 2027. Each restricted stock unit represents a contingent right to receive one share of BFRI common stock, subject to the company's discretion to settle the restricted stock units, in whole or in part, in cash, as discussed below in footnote 3. The reporting person received the restricted stock units as an award for no consideration. The restricted stock units vest in two equal yearly installments for the first two years following the grant date, beginning on March 4, 2027. Each vested restricted stock unit will be settled, at the Company's discretion, in shares, cash or a combination of shares and cash within 60 days of the vesting date. Options with different terms are not included

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones George Patrick

(Last) (First) (Middle)

660 MAIN STREET

FIRST FLOOR

(Street)

WOBURN, MA 01801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Biofrontera Inc. [ BFRI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/04/2026		A		50,000		(3)	(3)	Common Stock	50,000	$0	50,000	D
Employee stock option (right to buy)	$0.9	03/04/2026		A		50,000		(1)	03/04/2036	Common Stock	50,000	$0	50,000(4)	D

Explanation of Responses:

1. The option vests in two equal installments, the first of which will take place on September 4, 2026 and the second of which will take place on March 4, 2027.

2. Each restricted stock unit represents a contingent right to receive one share of BFRI common stock, subject to the company's discretion to settle the restricted stock units, in whole or in part, in cash, as discussed below in footnote 3. The reporting person received the restricted stock units as an award for no consideration.

3. The restricted stock units vest in two equal yearly installments for the first two years following the grant date, beginning on March 4, 2027. Each vested restricted stock unit will be settled, at the Company's discretion, in shares, cash or a combination of shares and cash within 60 days of the vesting date.

4. Options with different terms are not included

	/s/ Daniel Hakansson, Attorney-in-fact for George Jones	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Biofrontera (BFRI) grant to its Chief Commercial Officer?

Biofrontera granted its Chief Commercial Officer 50,000 restricted stock units and an option for 50,000 shares. Both awards were recorded as acquisitions at a grant price of $0.00 per share, functioning as stock-based compensation rather than open-market purchases.

How do the new restricted stock units for Biofrontera (BFRI) vest?

The 50,000 restricted stock units vest in two equal yearly installments starting March 4, 2027. Each vested unit will be settled within 60 days in shares, cash, or a combination, at the company’s discretion, and each unit represents a contingent right to one common share.

What is the vesting schedule of the new stock options at Biofrontera (BFRI)?

The option covering 50,000 shares vests in two equal installments. The first half vests on September 4, 2026, and the second half vests on March 4, 2027, providing a staged schedule for when the executive’s right to exercise fully becomes available.

Did the Biofrontera (BFRI) executive pay anything for these equity awards?

No cash was paid for these awards. The restricted stock units were received as an award for no consideration, and the option grant is recorded with a grant price of $0.00 per share, reflecting compensation rather than a cash purchase transaction.

How many derivative securities does the Biofrontera (BFRI) executive hold after these grants?

Following these grants, the executive is reported as holding 50,000 restricted stock units and 50,000 employee stock options. Each line of the filing shows 50,000 derivative securities as the total amount beneficially owned in that specific award category after the respective acquisition.